MétaCan
Menu
Back to cohort
Record W4286311985 · doi:10.1055/s-0042-1746380

Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial

2022· article· en· W4286311985 on OpenAlexaff
João Pedro Ferreira, Silvio E. Inzucchi, Bernard Zinman, Michaela Mattheus, Thomas Meinicke, Dominik Steubl, Christoph Wanner, Ursula Gotsch

Bibliographic record

VenueDiabetologie und Stoffwechsel · 2022
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsLunenfeld-Tanenbaum Research InstituteUniversity of TorontoMount Sinai Hospital
Fundersnot available
KeywordsEmpagliflozinMedicineGoutUric acidInternal medicineEMPAType 2 diabetesPlaceboDiabetes mellitusEndocrinologyChemistryAlternative medicine

Abstract

fetched live from OpenAlex

Background Higher serum uric acid (UA) levels are associated with gout and other adverse outcomes in patients with type 2 diabetes (T2D). Sodium glucose co-transporter 2 inhibitors lower UA and may reduce gout flares. We studied on-treatment effects of empagliflozin on serum UA levels, prescription of anti-gout/UA-lowering medication, and gout flares in 7020 patients (pooled empagliflozin n=4687; placebo n=2333) with T2D and high CV risk treated in EMPA-REG OUTCOME. Methods We assessed effects of empagliflozin versus placebo on UA levels using MMRM analyses; time-to-first occurrence of either an adverse event attributed to gout flare or anti-gout/UA-lowering medication initiation was assessed using Cox proportional hazards models. Results From Week 12 onwards, mean UA was reduced with pooled empagliflozin versus placebo; by Week 52, the adjusted mean treatment difference (95% CI) was -0.37 (-0.42, -0.31) mg/dl. Week 52 treatment difference was more pronounced in participants with baseline UA levels ≥ 6 mg/dl (-0.46 [-0.55, -0.38] mg/dl). Among 6,607 participants not taking UA-lowering medication at baseline, 5.2% of placebo participants experienced gout flare or initiated anti-gout/UA-lowering treatment versus 3.6% of pooled empagliflozin participants (incidence rates: 21.6 versus 14.1 events per 1,000 patient-years, respectively; hazard ratio [95% CI]: 0.67 [0.53, 0.85], P=0.001). Risk reduction was similar for both individual empagliflozin doses, and across participants with baseline UA levels below/above 6.0 mg/dl, and across participants with versus without history of gout at baseline (treatment-by-subgroup interaction P=0.53 and P=0.48, respectively). Conclusions Empagliflozin versus placebo reduced mean UA, occurrence of gout flares or initiation of UA-lowering medication. Publication History Article published online: 26 May 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.084
GPT teacher head0.316
Teacher spread0.233 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueDiabetologie und StoffwechselSame topicDiabetes Treatment and ManagementFrench-language works237,207